Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms
Liu M1, Wang J2, Yang Y3, An R4, Wen J5, Guan Z6, Zheng S7, Wang D8, Song B9, Liao L10, Guo H11, Xiao J12, Sun Y13, Shen Z14, Kong C15, He D16, Huang Y17, Wang X18, Zhang X19, Li H20, Huang J21, Zhao X22, Zeng P23, Song X24, Ye Z25. Chin Med J (Engl). 2014 Jan;127(2):261-5.

Author information

1Department of Urology, Beijing Hospital, Beijing 100730, China. 2Department of Urology, Beijing Hospital, Beijing 100730, China. Email: wangjy@bjhmoh.cn. 3Department of Urology, Beijing Chao-Yang Hospital, Beijing 100730, China. 4Department of Urology, The First Clinical College of Harbin Medical University, Harbin, Heilongjiang 150001, China. 5Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China. 6Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China. 7Department of Urology, Nan Fang Hospital, Guangzhou, Guandong 440100, China. 8Department of Urology, The First Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030012, China. 9Department of Urology, Southwest Hospital, Chongqing 400038, China. 10Department of Urology, China Rehabilitation Center, Beijing 100068, China. 11Department of Urology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China. 12Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, China. 13Department of Urology, Changhai Hospital of Shanghai, Shanghai 200433, China. 14Department of Urology, Ruijin Hospital Affiliated to The Shanghai Jiaotong University Medical School, Shanghai 200025, China. 15Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China. 16Department of Urology, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China. 17Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China. 18Department of Urology, Peking University People's Hospital, Beijing 100044, China. 19Department of Urology, The General Hospital of the People's Liberation Army, Beijing 100039, China. 20Department of Urology, Peking Union Medical College Hospital, Beijing 100005, China. 21Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China. 22Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China. 23Department of Urology, Wuhan Union Hospital, Wuhan, Hubei 430022, China. 24Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116600, China. 25Department of Urology, Tongji Hospital, Tongji Medical College Huazhong University of Science, Wuhan, Hubei 430030, China.


BACKGROUND: Overactive bladder (OAB) is a series of symptoms with high prevalence in elderly people. This study was conducted using the overactive bladder symptom score (OABSS) to evaluate the efficacy of solifenacin succinate for the treatment of OAB.

METHODS: This was a prospective, multicenter, single-arm, 12-week study that enrolled 241 OAB patients. The patients received 5-10 mg/day solifenacin. Changes in OABSS, symptoms from voiding diary, perception of bladder condition (PPBC) score, international prostate symptom score (IPSS) and quality of life (QOL) were evaluated at weeks 0, 4, and 12. The relationship between OABSS and PPBC score or parameters of voiding diary was also evaluated.

RESULTS: At baseline, the mean OABSS for all patients was 9.41±2.40, and was reduced significantly at week 12 (-3.76 points; 61.21%, P < 0.0001). The OABSS subscore, PPBC score, IPSS, and QOL were also significantly reduced during the study (P < 0.0001). The overall incidence of adverse events was 19.91% (44 cases). The gastrointestinal system was the most commonly affected (11.31%). Around 5.88% of the cases had adverse events related to the genitourinary system. There was a strong correlation between OABSS and urinary symptoms that was recorded in the 3-day voiding dairy.

CONCLUSIONS: We showed that solifenacin was clinically effective for relieving OAB symptoms, considering the balance between efficacy, patients' well-being, and tolerability. OABSS integrates four OAB symptoms into a single score and can be a useful tool for research and clinical practice.